Press Releases May 5, 2026 06:30 AM

embecta Announces Quarterly Cash Dividend

Embecta Corp. announces a small quarterly cash dividend of $0.01 per share.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
EMBC

Embecta Corp. declared a quarterly cash dividend of $0.01 per share, payable on June 15, 2026, to shareholders of record as of May 28, 2026. The company continues its focus on medical supplies and insulin delivery solutions.

embecta Announces Quarterly Cash Dividend
EMBC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Embecta declared a quarterly cash dividend of $0.01 per share.
  • Dividend payable on June 15, 2026, to shareholders of record May 28, 2026.
  • Embecta is a global medical supplies company specializing in insulin delivery and related solutions.

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 15, 2026 to stockholders of record at the close of business on May 28, 2026.

About embecta

embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

Contacts:     Media
Christian Glazar
Sr. Director, Corporate Communications
908-821-6922
Contact Media Relations Investors
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR



Risks

  • Low dividend amount may indicate limited cash flow or conservative capital allocation, possibly impacting investor sentiment.
  • Continued reliance on the medical supplies market, which can face regulatory and competitive risks.
  • Global operations subject the company to international market and supply chain uncertainties.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026